RecallRadar

FDA Drug recall D-0896-2023

PANCREAZE (pancrelipase) Delayed-Release Capsules, 100-count bottles, Rx only, Rx only, Manufactured by VIVUS LLC, Campbell, CA 95008, UPC:…

On 2023-07-19 the FDA classified a Class III recall of PANCREAZE (pancrelipase) Delayed-Release Capsules, 100-count bottles, Rx only, Rx only, Manufactured by VIVUS LLC, Campbell, CA 95008, UPC:… by Vivus, citing failed Stability Specifications.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0896-2023
ClassificationClass III
Statusongoing
Initiated2023-06-23
Published2023-07-19
Last updated2026-09-13 11:52 UTC
CompanyVivus
DistributionUS

Product

PANCREAZE (pancrelipase) Delayed-Release Capsules, 100-count bottles, Rx only, Rx only, Manufactured by VIVUS LLC, Campbell, CA 95008, UPC: N3 62541-401-10 5, NDC 62541-401-10,

Reason

Failed Stability Specifications

Identifiers

upc362541401105
ndc62541-402-10
ndc62541-403-10
ndc62541-404-10
ndc62541-405-10
ndc62541-401-10
ndc62541-406-50
ndc62541-406-10
code_infoLot #: 102101, Exp: 31 July 2024

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0896-2023%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.